OBJECTIVE: Fibroblast-like synoviocytes (FLS) are key players in the synovial pathology of rheumatoid arthritis (RA). Currently, there is no treatment that specifically targets these aggressive cells. By combining 3 different "omics" data sets, i.e., 1) risk genes in RA, 2) differentially expressed genes, and 3) differential DNA methylation in RA versus osteoarthritis (OA) FLS, we identified LBH (limb bud and heart development) as a candidate gene in RA. The present study was undertaken to define the role of this gene in FLS. METHODS: Synovial tissue specimens from RA and OA patients were collected at the time of joint replacement surgery. LBH expression was silenced using small interfering RNA or overexpressed using an LBH expression vector in primary FLS. Gene expression profiles were determined by microarray and assessed using Ingenuity Pathway Analysis. Effects of modified LBH expression were investigated in functional assays. RESULTS: LBH was expressed in the synovial lining layer in patients with RA. Transforming growth factor β1 significantly increased LBH expression in primary FLS, and platelet-derived growth factor BB decreased it. Pathway analysis of the transcriptome of LBH-deficient FLS compared to control FLS identified "cellular growth and proliferation" as the most significantly enriched pathway. In growth assays, LBH deficiency increased FLS proliferation. Conversely, LBH overexpression significantly inhibited cell growth. Cell cycle analysis demonstrated a marked increase in cells entering the cell cycle in LBH-deficient FLS compared to controls. LBH did not alter apoptosis. CONCLUSION: LBH is a candidate gene for synovial pathology in RA. It is regulated by growth factors and modulates cell growth in primary FLS. Our data suggest a novel mechanism for synovial intimal hyperplasia and joint damage in RA.
OBJECTIVE: Fibroblast-like synoviocytes (FLS) are key players in the synovial pathology of rheumatoid arthritis (RA). Currently, there is no treatment that specifically targets these aggressive cells. By combining 3 different "omics" data sets, i.e., 1) risk genes in RA, 2) differentially expressed genes, and 3) differential DNA methylation in RA versus osteoarthritis (OA) FLS, we identified LBH (limb bud and heart development) as a candidate gene in RA. The present study was undertaken to define the role of this gene in FLS. METHODS: Synovial tissue specimens from RA and OApatients were collected at the time of joint replacement surgery. LBH expression was silenced using small interfering RNA or overexpressed using an LBH expression vector in primary FLS. Gene expression profiles were determined by microarray and assessed using Ingenuity Pathway Analysis. Effects of modified LBH expression were investigated in functional assays. RESULTS:LBH was expressed in the synovial lining layer in patients with RA. Transforming growth factor β1 significantly increased LBH expression in primary FLS, and platelet-derived growth factor BB decreased it. Pathway analysis of the transcriptome of LBH-deficient FLS compared to control FLS identified "cellular growth and proliferation" as the most significantly enriched pathway. In growth assays, LBH deficiency increased FLS proliferation. Conversely, LBH overexpression significantly inhibited cell growth. Cell cycle analysis demonstrated a marked increase in cells entering the cell cycle in LBH-deficient FLS compared to controls. LBH did not alter apoptosis. CONCLUSION:LBH is a candidate gene for synovial pathology in RA. It is regulated by growth factors and modulates cell growth in primary FLS. Our data suggest a novel mechanism for synovial intimal hyperplasia and joint damage in RA.
Authors: Lucia A Hindorff; Praveen Sethupathy; Heather A Junkins; Erin M Ramos; Jayashri P Mehta; Francis S Collins; Teri A Manolio Journal: Proc Natl Acad Sci U S A Date: 2009-05-27 Impact factor: 11.205
Authors: Stephanie Lefèvre; Anette Knedla; Christoph Tennie; Andreas Kampmann; Christina Wunrau; Robert Dinser; Adelheid Korb; Eva-Maria Schnäker; Ingo H Tarner; Paul D Robbins; Christopher H Evans; Henning Stürz; Jürgen Steinmeyer; Steffen Gay; Jürgen Schölmerich; Thomas Pap; Ulf Müller-Ladner; Elena Neumann Journal: Nat Med Date: 2009-11-08 Impact factor: 53.440
Authors: Alexandra Zhernakova; Eli A Stahl; Gosia Trynka; Soumya Raychaudhuri; Eleanora A Festen; Lude Franke; Harm-Jan Westra; Rudolf S N Fehrmann; Fina A S Kurreeman; Brian Thomson; Namrata Gupta; Jihane Romanos; Ross McManus; Anthony W Ryan; Graham Turner; Elisabeth Brouwer; Marcel D Posthumus; Elaine F Remmers; Francesca Tucci; Rene Toes; Elvira Grandone; Maria Cristina Mazzilli; Anna Rybak; Bozena Cukrowska; Marieke J H Coenen; Timothy R D J Radstake; Piet L C M van Riel; Yonghong Li; Paul I W de Bakker; Peter K Gregersen; Jane Worthington; Katherine A Siminovitch; Lars Klareskog; Tom W J Huizinga; Cisca Wijmenga; Robert M Plenge Journal: PLoS Genet Date: 2011-02-24 Impact factor: 5.917
Authors: Anna-Karin H Ekwall; Thomas Eisler; Christian Anderberg; Chunsheng Jin; Niclas Karlsson; Mikael Brisslert; Maria I Bokarewa Journal: Arthritis Res Ther Date: 2011-03-07 Impact factor: 5.156
Authors: Marjan M C Steenvoorden; Tanja C A Tolboom; Gabri van der Pluijm; Clemens Löwik; Cornelis P J Visser; Jeroen DeGroot; Adriana C Gittenberger-DeGroot; Marco C DeRuiter; Bert J Wisse; Tom W J Huizinga; René E M Toes Journal: Arthritis Res Ther Date: 2006 Impact factor: 5.156
Authors: David L Boyle; Sanna Rosengren; William Bugbee; Arthur Kavanaugh; Gary S Firestein Journal: Arthritis Res Ther Date: 2003-10-08 Impact factor: 5.156
Authors: Deepa Hammaker; John W Whitaker; Keisuke Maeshima; David L Boyle; Anna-Karin H Ekwall; Wei Wang; Gary S Firestein Journal: Arthritis Rheumatol Date: 2016-11 Impact factor: 10.995